Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Receivables (2021 - 2023)

Relay Therapeutics (RLAY) has disclosed Change in Receivables for 3 consecutive years, with -$211000.0 as the latest value for Q4 2023.

  • Quarterly Change in Receivables fell 424.62% to -$211000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$306000.0 through Dec 2023, down 215.46% year-over-year, with the annual reading at -$306000.0 for FY2023, 215.46% down from the prior year.
  • Change in Receivables for Q4 2023 was -$211000.0 at Relay Therapeutics, down from $133000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $525000.0 in Q3 2021, with the low at -$75.0 million in Q1 2021.
  • Average Change in Receivables over 3 years is -$6.3 million, with a median of -$33500.0 recorded in 2022.
  • Peak annual rise in Change in Receivables hit 382.98% in 2023, while the deepest fall reached 1194.74% in 2023.
  • Over 3 years, Change in Receivables stood at -$401000.0 in 2021, then surged by 116.21% to $65000.0 in 2022, then tumbled by 424.62% to -$211000.0 in 2023.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$211000.0, $133000.0, and -$208000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.